OBJECT: Despite the increasing use of immunotherapy in the treatment of metastatic melanoma, the effects of this therapy on the management of patients with associated brain metastases are not completely defined. The authors undertook this study to determine the effectiveness of resection and the effects of immunotherapy on brain metastasis management. METHODS: The authors analyzed data pertaining to consecutive patients with metastatic melanoma treated with immunotherapy within 3 months of discovery of brain metastases that were surgically resected. RESULTS: Forty-one patients (median age 44.4 years, range 19.2-63.1 years) underwent resection of 53 brain metastases (median number of metastases 1, range 1-4). The median metastasis volume was 2.5 cm(3). Fifteen patients underwent whole-brain radiation therapy (WBRT) and 26 patients did not. Duration of survival from brain metastasis diagnosis was not significantly different between patients who received WBRT (mean 24.9 months) and those who did not (mean 23.3 months) (p > 0.05). Local and distant brain recurrence rates were not statistically different between the WBRT (7.1% and 28.6%, respectively) and non-WBRT (7.7% and 41.0%) groups for the duration of follow-up (p > 0.05). An objective systemic response to immunotherapy was associated with increased duration of survival (p < 0.05). CONCLUSIONS: Resection of melanoma brain metastases in patients treated with immunotherapy provides excellent local control with low morbidity. An objective response to systemic immunotherapy is associated with a prolonged survival in patients who have undergone resection of melanoma brain metastases. Moreover, adjuvant WBRT in melanoma immunotherapy patients with limited metastatic disease to the brain does not appear to provide a significant survival benefit.
OBJECT: Despite the increasing use of immunotherapy in the treatment of metastatic melanoma, the effects of this therapy on the management of patients with associated brain metastases are not completely defined. The authors undertook this study to determine the effectiveness of resection and the effects of immunotherapy on brain metastasis management. METHODS: The authors analyzed data pertaining to consecutive patients with metastatic melanoma treated with immunotherapy within 3 months of discovery of brain metastases that were surgically resected. RESULTS: Forty-one patients (median age 44.4 years, range 19.2-63.1 years) underwent resection of 53 brain metastases (median number of metastases 1, range 1-4). The median metastasis volume was 2.5 cm(3). Fifteen patients underwent whole-brain radiation therapy (WBRT) and 26 patients did not. Duration of survival from brain metastasis diagnosis was not significantly different between patients who received WBRT (mean 24.9 months) and those who did not (mean 23.3 months) (p > 0.05). Local and distant brain recurrence rates were not statistically different between the WBRT (7.1% and 28.6%, respectively) and non-WBRT (7.7% and 41.0%) groups for the duration of follow-up (p > 0.05). An objective systemic response to immunotherapy was associated with increased duration of survival (p < 0.05). CONCLUSIONS: Resection of melanoma brain metastases in patients treated with immunotherapy provides excellent local control with low morbidity. An objective response to systemic immunotherapy is associated with a prolonged survival in patients who have undergone resection of melanoma brain metastases. Moreover, adjuvant WBRT in melanoma immunotherapy patients with limited metastatic disease to the brain does not appear to provide a significant survival benefit.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Lisa M Guirguis; James C Yang; Donald E White; Seth M Steinberg; David J Liewehr; Steven A Rosenberg; Douglas J Schwartzentruber Journal: J Immunother Date: 2002 Jan-Feb Impact factor: 4.456
Authors: Jenny J Hong; Steven A Rosenberg; Mark E Dudley; James C Yang; Donald E White; John A Butman; Richard M Sherry Journal: Clin Cancer Res Date: 2010-08-18 Impact factor: 12.531
Authors: K M Fife; M H Colman; G N Stevens; I C Firth; D Moon; K F Shannon; R Harman; K Petersen-Schaefer; A C Zacest; M Besser; G W Milton; W H McCarthy; J F Thompson Journal: J Clin Oncol Date: 2004-04-01 Impact factor: 44.544
Authors: Ugur Selek; Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela Allen; Jeffrey Weinberg; Raymond Sawaya; Moshe H Maor Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Andrew E Radbill; John F Fiveash; Elizabeth T Falkenberg; Barton L Guthrie; Paul E Young; Sreelatha Meleth; James M Markert Journal: Cancer Date: 2004-08-15 Impact factor: 6.860
Authors: Akash J Patel; Dima Suki; Mustafa Aziz Hatiboglu; Hiba Abouassi; Weiming Shi; David M Wildrick; Frederick F Lang; Raymond Sawaya Journal: J Neurosurg Date: 2010-08 Impact factor: 5.115
Authors: Anthony L Asher; Mohammed Ali Alvi; Mohamad Bydon; Nader Pouratian; Ronald E Warnick; James McInerney; Inga S Grills; Jason Sheehan Journal: J Neurooncol Date: 2021-01-22 Impact factor: 4.130
Authors: Diego M Marzese; Richard A Scolyer; Jamie L Huynh; Sharon K Huang; Hajime Hirose; Kelly K Chong; Eiji Kiyohara; Jinhua Wang; Neal P Kawas; Nicholas C Donovan; Keisuke Hata; James S Wilmott; Rajmohan Murali; Michael E Buckland; Brindha Shivalingam; John F Thompson; Donald L Morton; Daniel F Kelly; Dave S B Hoon Journal: Hum Mol Genet Date: 2013-09-06 Impact factor: 6.150
Authors: S Harrison Farber; Vadim Tsvankin; Jessica L Narloch; Grace J Kim; April K S Salama; Gordana Vlahovic; Kimberly L Blackwell; John P Kirkpatrick; Peter E Fecci Journal: Oncoimmunology Date: 2016-04-11 Impact factor: 8.110
Authors: Jaclyn C Flanigan; Lucia B Jilaveanu; Mark Faries; Mario Sznol; Stephan Ariyan; James B Yu; Jonathan P S Knisely; Veronica L Chiang; Harriet M Kluger Journal: Curr Probl Cancer Date: 2011 Jul-Aug Impact factor: 3.187
Authors: Christopher Alvarez-Breckenridge; Anita Giobbie-Hurder; Corey M Gill; Mia Bertalan; Jackson Stocking; Alexander Kaplan; Naema Nayyar; Donald P Lawrence; Keith T Flaherty; Helen A Shih; Kevin Oh; Tracy T Batchelor; Daniel P Cahill; Ryan Sullivan; Priscilla K Brastianos Journal: Oncologist Date: 2019-02-22
Authors: Gautham Gampa; Shruthi Vaidhyanathan; Brynna-Wilken Resman; Karen E Parrish; Svetomir N Markovic; Jann N Sarkaria; William F Elmquist Journal: Curr Pharmacol Rep Date: 2016-11-09
Authors: Haitao Fan; Ian Zhang; Xuebo Chen; Leying Zhang; Huaqing Wang; Anna Da Fonseca; Edwin R Manuel; Don J Diamond; Andrew Raubitschek; Behnam Badie Journal: Clin Cancer Res Date: 2012-08-17 Impact factor: 12.531
Authors: Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman Journal: Am J Clin Dermatol Date: 2013-06 Impact factor: 7.403